‘Nature Communications’ publishes new gene writing technology to allow for more effective and safe advanced therapies
Developed by researchers at the Translational Synthetic Biology Lab at the Pompeu Fabra University (UPF) led by Dr Marc Güell. UPF has transferred the technology to Integra Tx.
Integra Therapeutics secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures
The investment will be used to develop an innovative gene writing platform with the potential to make advanced therapies safer and more effective.